Semma Therapeutics appoints Mark Fishman as chairman
Dr. Fishman is currently Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Service in Medicine at the MGH.
He served for 13 years as the founding President of the Novartis Institutes for BioMedical Research, appointed in 2002 to devise and implement a new global strategy for Novartis' drug discovery effort.
Before joining Novartis, Dr. Fishman was Chief of Cardiology and founding Director of the Cardiovascular Research Center at Massachusetts General Hospital-
Dr. Fishman was Professor of Medicine at Harvard Medical School where his laboratory discovered many of the genes that drive formation of vertebrate organs, doing so thorough one of the first large scale genetic screens in the zebrafish.
Dr. Fishman completed his internal medicine residency, chief residency and cardiology training at Massachusetts General Hospital.
He graduated with a bachelor’s degree from Yale College in the US in 1972, and with an M.D. from Harvard Medical School in 1976.
Dr. Fishman has been honored with many awards and distinguished lectureships, is a fellow of the American Academy of Arts and Sciences, serves on the council of the National Academy of Medicine. ■
LATEST MOVES FROM Massachusetts
- Intellia Therapeutics appoints two directors
- Dunkin' Brands names Roland Smith to board
- Radius Health appoints Jesper Høiland as CEO
- Athenahealth announces CFO transition
- Analogic Corporation appoints Michael Bourque as CFO
More inside POST
EasyHotel sales increased 24.7% Earnings